BFLY vs. NVCR, SSII, ESTA, CDRE, BLFS, PLSE, MDXG, KMTS, INMD, and IRMD
Should you be buying Butterfly Network stock or one of its competitors? The main competitors of Butterfly Network include NovoCure (NVCR), SS Innovations International (SSII), Establishment Labs (ESTA), Cadre (CDRE), BioLife Solutions (BLFS), Pulse Biosciences (PLSE), MiMedx Group (MDXG), Kestra Medical Technologies (KMTS), InMode (INMD), and iRadimed (IRMD). These companies are all part of the "medical equipment" industry.
Butterfly Network vs. Its Competitors
NovoCure (NASDAQ:NVCR) and Butterfly Network (NYSE:BFLY) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.
84.6% of NovoCure shares are owned by institutional investors. Comparatively, 37.9% of Butterfly Network shares are owned by institutional investors. 5.5% of NovoCure shares are owned by company insiders. Comparatively, 25.2% of Butterfly Network shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
NovoCure presently has a consensus price target of $28.79, suggesting a potential upside of 140.28%. Butterfly Network has a consensus price target of $3.00, suggesting a potential upside of 96.72%. Given NovoCure's higher possible upside, research analysts plainly believe NovoCure is more favorable than Butterfly Network.
In the previous week, NovoCure had 1 more articles in the media than Butterfly Network. MarketBeat recorded 5 mentions for NovoCure and 4 mentions for Butterfly Network. Butterfly Network's average media sentiment score of 1.73 beat NovoCure's score of 0.63 indicating that Butterfly Network is being referred to more favorably in the news media.
NovoCure has a net margin of -27.13% compared to Butterfly Network's net margin of -71.79%. Butterfly Network's return on equity of -30.53% beat NovoCure's return on equity.
Butterfly Network has lower revenue, but higher earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Butterfly Network, indicating that it is currently the more affordable of the two stocks.
NovoCure has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500. Comparatively, Butterfly Network has a beta of 2.52, indicating that its share price is 152% more volatile than the S&P 500.
Summary
Butterfly Network beats NovoCure on 9 of the 16 factors compared between the two stocks.
Get Butterfly Network News Delivered to You Automatically
Sign up to receive the latest news and ratings for BFLY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BFLY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Butterfly Network Competitors List
Related Companies and Tools
This page (NYSE:BFLY) was last updated on 9/4/2025 by MarketBeat.com Staff
Free BFLY Stock Alerts